newsfilter
← Latest News
Business Wire·

Sierra Oncology Reports Baseline Ferritin Differentially Predicts Week 24 Transfusion Independence Response in Myelofibrosis Patients

Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced data from new retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate base